Diligence memo · auto-generated · as of July 3, 2026

Cyana Therapeutics, LLC

Cyana Therapeutics, LLC looks under-valued against its niche peers and is active on financing cadence.

SourceModeled below same-niche peers while still financing on rhythm — a potential mispricing worth a closer look.

Businessfiled

Cyana Therapeutics, LLC operates in Pharma, based in MIAMI BEACH.

Sub-sector tags: pharma.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Cyana Therapeutics, LLC has raised $151K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $151K on 2025-11-27.

Most recent recorded round closed around 2025-11-27.

Valuation (modeled)modeled

Provath models Cyana Therapeutics, LLC at approximately $300K (range $85K–$658K). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.47× the median modeled value of Pre-Seed Pharma companies in 2025–2027 (8 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Last raise 7 mo ago; this sector typically re-raises about every 16 months.

Raising on or ahead of the sector's normal rhythm.

Comparablesmixed

Capital scale ranks ahead of 20% of Pharma peers (310 compared).

Modeled value ranks above 17% of those peers.

Closest niche peers: Mizar Therapeutics, Inc., ReEngage Therapeutics, Inc., King Therapeutics LLC, Dnp Therapeutics Inc, Protibea Therapeutics, Inc..

Peoplefiled

2 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.